Strategic Contract2026-05-26

IVIM Tech secures 617M KRW bio-microscope contract

IVI

아이빔테크놀로지

460470

+0.45

Signal Score

51CNeutral
Score51 / 100

Historical Avg Return (5d)

+0.11%

Data Coverage

100%n=757

Risk-adjusted indicator based on 757 historical DART filings. For informational purposes only — not investment advice.

Financial Impact

POSITIVE

Key Numbers

  • • Contract Amount: 617,423,827 KRW (USD 407,998.30)
  • • % of Recent Revenue: 14.1%
  • • Recent Annual Revenue (2025): 4,375,864,077 KRW
  • • Contract Period: May 25, 2026 – October 24, 2026

AI Analysis Summary

IVIM Technology has secured a supply contract for bio-microscopes worth 617.42 million KRW (USD 407,998.30) with Crisel Instruments SRL, representing 14.1% of its 2025 revenue. The final customer is CHIESI PHARMACEUTICAL in Italy. The contract period is from May 25, 2026, to October 24, 2026, with payment due within 60 days after internal inspection, which is expected by August 25, 2026. This contract is a positive development, contributing significantly to future revenue.

How This Event Is Evaluated

Strategic Contract Evaluation

Contract events are evaluated by measuring business scale, revenue relevance, counterparty quality, and execution visibility.

AI is used to interpret disclosures and extract structured data.

Signal scores are generated using event-specific methodologies and quantitative models.

  • Contract size relative to company revenue
  • Expected revenue impact
  • Counterparty quality
  • Contract duration and execution period
Read our full scoring methodology →

Track Korean Market Signals — Free

Sign up free to access live disclosures, AI analysis, and event filters.

Public Beta · No credit card required

This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.

AI-processed analysis. Based on: 단일판매ㆍ공급계약체결 . Source: Financial Supervisory Service (금융감독원 전자공시시스템). Raw government data is not redistributed. Not investment advice.